A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Gastrointestinal TumorsSolid Tumor

Interventions

DRUG

GNC-077

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Beijing Cancer Hospital, Beijing

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY